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Abstract.  When NIH 3T3 cells were transfected with 
the cDNA for basic fibroblast growth factor (bFGF), 
most cells displayed a transformed phenotype. Acquisi- 
tion of a transformed phenotype was correlated with 
the expression of high levels of bFGF (Quarto et al., 
1989).  Cells that had been transformed as a result of 
transfection with bFGF cDNA had a decreased capac- 
ity to bind  ~25I-bFGF to high affinity receptors.  NIH 
3T3 cells transfected with bFGF cDNA that expressed 
lower levels of bFGF were not transformed and had a 
normal number of bFGF receptors. NIH 3T3 cells 
transfected with the hst/Kfgf oncogene, which encodes 
a  secreted molecule with 45 % homology to bFGE 
also displayed a transformed phenotype and decreased 
numbers of bFGF receptors. However,  NIH 3T3 cells 
transfected with the H-ras oncogene were transformed 
but had a normal number of bFGF receptors.  Thus, 
transformation by bFGF-like molecules resulted in 
downregulation of bFGF receptors. Receptor number 
was not affected by cell density for both parental NIH 
3T3 cells and transformed cells. In the cells trans- 
fected with bFGF cDNA that were not transformed, 
the receptors could be downregulated in response to 
exogenous bFGE Conditioned medium from trans- 
formed transfected cells contained sufficient quantities 
of bFGF to downregulate bFGF receptors on parental 
NIH 3T3 cells.  Thus, the downregulation of bFGF 
receptors seemed related to the presence of bFGF in 
an extracytoplasmic compartment. Treatment of the 
transformed transfected NIH 3T3 cells with suramin, 
which blocks the interaction of bFGF with its recep- 
tor, reversed the morphological transformation and re- 
stored receptors almost to normal numbers. These 
results demonstrate that in these cells bFGF transforms 
cells by interacting with its receptor and that bFGF 
and hst/K-fgf  may use the same receptor. 
B 
ASIC fibroblast growth factor CoFGF)  ~ stimulates the 
growth and modulates the differentiated function of 
cells of mesenchymal,  ectodermal,  and endodermal 
origin (Gospodarowicz et al., 1987; Rifldn and Moscatelli, 
1989). Acidic FGF (aFGF), a polypeptide mitogen with a 
55 % amino acid sequence homology to bFGE shares many 
of the  same  biological  properties  (Gospodarowicz  et al., 
1987). The overlap in biological activities may be due to the 
fact that in several cell  types these two mitogens seem to 
share  the  same  receptors  (Neufeld  and  Gospodarowicz, 
1986;  Huang  et  al.,  1986; Olwin  and  Hauschka,  1986; 
Hoshi et al.,  1988). Recently, three oncogenes  have been 
identified that code for proteins with 40-45 % sequence ho- 
mology to bFGF (Taira et al.,  1987; Yoshida et al.,  1987; 
Delli-Bovi et al., 1987; Dickson and Peters,  1987; Zhan et 
1. Abbreviations  used in this paper: aFGE acidic fibroblast growth factor; 
bFGF, basic fibroblast growth factor; PDGF, platelet-derived  growth factor. 
al., 1988). The product of  one of  these oncogenes, hst/K-fg~, 
has been  partially  characterized  and has  many biological 
properties in common with bFGF (Delli-Bovi et al., 1988). 
The hst/K-fgf  protein also seems to use the same receptors 
as bFGF (unpublished observations). 
Receptors for bFGF have been identified on a variety of 
cell types (Neufeld and Gospodarowicz,  1985; Olwin and 
Hauschka,  1986; Moenner et al.,  1986; Moscatelli,  1987; 
Neufeld et al.,  1987; Neufeld and Gospodarowicz,  1988; 
Presta et al., 1988). In many cell types, two putative receptor 
proteins of 125,000 and  145,000 molecular  weight can be 
cross-linked to radiolabeled bFGE Some variation in size of 
the  receptor  among  various  cell  types  has  been  reported 
(Neufeld  and  Gospodarowicz,  1988). Occupation  of the 
receptor leads to internalization of bFGF and a decrease in 
the number of cell surface receptors (Neufeld and Gospoda- 
rowicz, 1985; Moscatelli,  1988). For several cell types, the 
number of receptors per cell seems to be roughly inversely 
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Tsuboi, R., Y. Sato, and D. B. Rifkin, manuscript submitted 
for publication). This apparent downregulation of receptors 
in cells that produce bFGF may be related to the observation 
that bFGF acts in an autocrine manner in some cell types 
(Sato and Rifkin,  1988). 
In addition to binding to receptors, bFGF also binds to 
heparan sulfate proteoglycans produced by the cell (Mosca- 
telli, 1987; Saksela et al.,  1988). It is unclear whether these 
heparan sulfate proteoglycans are cell-surface molecules or 
components of the extraceUular matrix or both. For the pur- 
poses of this discussion, the term matrix will refer to all of 
these possibilities. The binding of bFGF to the ceU-associ- 
ated heparan sulfate proteoglycans can complicate the mea- 
surement of bFGF receptors. However, bFGF bound to ma- 
trix can be separated from bFGF bound to the receptor by 
washing  cells with  2  M  NaCI  at neutral pH  (Moscatelli, 
1987). The 2 M NaC1 wash removes bFGF bound to matrix 
while the bFGF bound to receptors remains cell associated. 
A subsequent wash with 2 M NaCI at pH 4.0 removes bFGF 
bound to receptors. These procedures can be used to quanti- 
tate bFGF receptors despite high levels of bFGF binding to 
matrix. 
Both bFGF and aFGF lack a conventional signal sequence 
for secretion and appear to be localized primarily within the 
cell. It thus is unclear how these growth factors interact with 
cell  surface receptors in  autocrine  systems.  Cells  with  a 
transformed phenotype as a result of transfection with genes 
of the FGF family can be viewed as a model for an autocrine 
system using FGE Cells transfected with bFGF to which the 
immunoglobulin signal  sequence has been spliced have a 
transformed phenotype,  suggesting  that  in  these cells the 
bFGF is secreted and interacts with bFGF receptors in an ex- 
tracytoplasmic compartment (Rogelj et al., 1988). However, 
in these experiments no bFGF could be detected in the condi- 
tioned medium of these cells  (Rogelj et al.,  1988).  Cells 
producing a high level of unmodified bFGF or aFGF also ap- 
pear to be transformed (Neufeld et al.,  1988; Sasada et al., 
1988; Jaye et al.,  1988; Quarto et al.,  1989). In the case of 
aFGF, no decrease in receptor level was detected in the trans- 
formed cells (Jaye et al., 1988). This finding raises the possi- 
bility that FGFs can transform without interacting with their 
receptors. It recently has been shown that in NIH 3T3 cells 
transfected with bFGF, transformation is related to the level 
of bFGF expression (Quarto et al.,  1989). Here we demon- 
strate that in these cells transformation is also correlated with 
a decrease in receptor number, suggesting that bFGF trans- 
forms through an interaction with its receptor. 
Materials and Methods 
Reagents 
bFGF was purified from human placentas as described previously (Mosca- 
telli et al., 1986b; Presta et al., 1986). Recombinant bFGF was a gift from 
Synergen,  Inc.  (Boulder,  CO).  Natural  and recombinant bFGF  behaved 
similarly and were  used interchangeably, bFGF  was iodinated using the 
Iodo-Gen reagent (Pierce Chemical Co., Rockford, IL) as described previ- 
ously (Neufeld and Gospodarowicz,  1985;  Moscatelli,  1987).  t25I-bFGF 
had a  specific activity of •500  cpm/fmol. 
Cells 
Mouse NIH  3T3  cells were  transfected with the retroviral  vector pZip- 
NeoSV(X) alone, pZipNeoSV(X) containing a human bFGF cDNA insert, 
or pZipNeoSV(X) containing an hst/K-fgfcDNA insert as described previ- 
ously (Quarto et al.,  1989). Briefly, 3  x  105 NIH 31"3 cells/100-mm plate 
were transfected with a calcium phosphate precipitate containing 0.5/~g of 
plasmid DNA and 20/~g of NIH 3T3 high-molecular weight DNA. After 
24 h in culture, the cells were split 1:5 and cultured thereafter in DME con- 
raining 10%  calf serum (Gibco Laboratories, Grand Island, NY) and 500 
#g/ml of G418 (Gibco Laboratories). After 2 wk, the G418-resistant clones 
were isolated and expanded, and the cells were analyzed. In some experi- 
ments, NIH 3T3 cells transfected with pZipNeoSV(X) containing a mutated 
bFGF eDNA insert were used. Mutations were made as described by Flor- 
kiewicz and Sommer (1989). In the mutant 365 bFGF eDNA, the ATG (met) 
codon at nucleotide positions 364-366 initiating translation of 18 kD bFGF 
was changed to GCT (ala). In the mutant 43 bFGF eDNA, a  17-nucleotide 
sequence was inserted between nucleotides 352 and 353 causing  a  +1 frame 
shift for the bFGF species initiating translation 5' to the start codon for 18 
kD bFGE 
NIH 3T3 cells transfected with the H-ras oncogene were provided by Dr. 
Claudio Basilico of the New York University Medical Center (New York). 
Determination of  High-aJSinity Binding of  nSI-bFGF 
Cells were plated at 1 ×  106 per 60-mm dish. After 36 h at 37°C, the cul- 
tures were washed twice with cold PBS and incubated for 2 h at 4°C in DME 
containing 0.15% gelatin, 25 mM Hepes, pH 7.4, and 10 ng/ml 125I-bFGE 
This concentration of 125I-bFGF was sufficient to saturate bFGF receptors. 
To control for nonspecific binding, parallel cultures were incubated under 
the same conditions with the addition of 200-fold excess unlabeled bFGE 
At the end of the incubation period, the medium was removed, and the cells 
were washed once with PBS and twice with 2 M  NaCI in 20 mM Hepes, 
pH 7.4, to remove 125I-bFGF bound to the extracellular matrix (Moscatelli, 
1987).  125I-bFGF  bound  to  receptors  was  released  by  two  subsequent 
washes with 2 M NaCI in 20 mM sodium acetate, pH 4.0 (Moscatelli, 1987, 
1988). The amount of radioactivity released in the washes was determined 
in  a  gamma  scintillation  counter  (model  5210;  Packard  Instruments, 
Downers Grove, IL). Parallel cultures were trypsinized, and the number of 
cells per culture was determined with a  particle  counter (Coulter Elec- 
tronics, Hialeah, FL). 
In some experiments, cells were washed twice with cold 2  M  NaCI in 
20 mM sodium acetate, pH 4.0, and twice with cold PBS before incubation 
with t2~I-bFGF  to remove any bFGF already bound to the cells. 
Cross-Linking of ~Zsl-bFGF  to Cells 
Cells were washed twice with cold 2 M  NaCI in 20 mM sodium acetate, 
pH 4.0, and twice with cold PBS and were incubated in DME containing 
0.15% gelatin, 25 mM Hepes, pH 7.4, and 10 ng/ml 125I-bFGF for 2 h at 
4°C. The medium was removed and replaced with PBS containing 1 mM 
bis(suifosuccinimidyl)suberate  (Pierce Chemical Co.) and 10% DMSO. Af- 
ter a  15-min incubation at room temperature, the cells were extracted with 
electrophoresis sample buffer and the extract was heated for 2 min in a boil- 
ing water bath. The samples were subjected to SDS-PAGE on a 3 % stacking 
gel and a 5-15% gradient resolving gel. The gels were dried and exposed 
to Kodak X-MAR (Eastman Kodak, Rochester, NY) autoradiography film. 
Suramin Treatment of Cells 
24 h after plating the cells, the medium of cultures was changed to fresh 
DME containing 10%  calf serum with or without 1 mM suramin (Mobay 
Chemical Corp., New York, NY). After a 12-h incubation at 37°C, the cells 
were washed twice with PBS and incubated for a further 24 h in DME con- 
raining 10%  calf serum with or without  1 mM suramin. The cells were 
washed twice with cold 2 M  NaCI in 20 mM sodium acetate, pH 4.0, and 
twice with cold PBS and used for binding studies. To compensate for the 
fact that the cells treated with suramin did not grow during the treatment, 
these cultures were plated at  1.0  x  106 cells per 60-ram dish, while un- 
treated cultures were plated at 0.5  x  106 cells per 60-mm dish. 
Western Blot Analysis of  Suramin-treated Cells 
Untreated clone B3 cells and cells treated with 1 mM suramin for 36 h as 
described above were washed twice with cold PBS, scraped from the plate 
in PBS, sonicated for 1 rain at 20 W, and heated in a boiling water bath for 
5 min. 40/~g of the cell sonicate was subjected to SDS-PAGE on a 3 % stack- 
ing gel and a 12% resolving gel. The gel was electroblotted onto a nitrocel- 
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to  high-affinity  receptors  on 
transfected and nontransfected 
NIH 3T3 cells. Cultures con- 
mining ~1.5  x  l& cells/60- 
mm  dish  of  nontransfected 
NIH  3T3  cells  (column  1), 
clone  B3  cells  (column  2), 
clone  BI4 cells  (column  3), 
NIH 3T3 cells transfected with 
the Zip plasmid only (column 
4),  or NIH 3T3  cells  trans- 
fected with  the  hst/K-fgf on- 
cogene  (column  5)  were  in- 
cubated  for 2  h  at 4°C  with 
DME containing 0.15% gela- 
tin  and  10  ng/ml  z25I-bFGE 
The cells  were  washed  once 
with PBS and twice with 2 M NaCI in 20 mM Hepes, pH 7.4, to 
remove t25I-bFGF bound to matrix.  ~25I-bFGF  bound to receptors 
was removed by two washes with 2 M NaCI in 20 mM sodium ace- 
tate, pH 4.0, and was quantitated in a gamma scintillation counter. 
Nonspecific binding was determined by incubating parallel cultures 
with the above solution containing a 200-fold excess of unlabeled 
bFGE 
lulose filter. The blot was probed for 30 min at room temperature with anti- 
bFGF antibodies diluted 1:200 in 10 mM Tris-HC1,  pH 8.0, 150 mM NaCI, 
0.1% Tween 20, plus 5% nonfat dry milk, washed three times with the same 
buffer, and incubated with 125I-protein A  (New England Nuclear, Boston, 
MA) in 10 mM Tris-HCl, pH 8.0, 150 mM NaCI, 0.1% Tween 20, plus 0.5% 
gelatin for 30 min at room temperature. After three washes in the same 
buffer, the filter was dried and exposed to Kodak X-MAR film. The intensity 
of  the bands on the autoradiogram were compared after scanning with a soft 
laser densitometer. 
Results 
NIH  3T3  cells  normally  produce  undetectable  levels  of 
bFGE When these cells were transfected with bFGF cDNA, 
clones  were  isolated  that  express  0.66  pg/cell  of  bFGF 
(Quarto et al., 1989), 300 times as much bFGF as expressed 
by SK-HEP-1 human hepatoma cells, which are among the 
Figure 2.  Cross-linking  of  *2sI- 
bFGF to high  affinity receptors 
on transfected and nontransfected 
NIH 3T3 cells.  Cultures  of non- 
transfected  NIH 3T3  cells  (lane 
1), clone B3 cells (lane 2), clone 
BI4 cells (lanes 3), NIH 3T3 cells 
transfected with the Zip plasmid 
only (lane 4), or NIH 3T3 cells 
transfected with the hst/K-fgf on- 
cogene  (lane  5)  were  incubated 
for 2 h at 4°C with DME contain- 
ing 0.15% gelatin and  10 ng/ml 
12~I-bFGE The cells were washed 
with  PBS and incubated  in PBS 
containing  I mM bis(sulfosucci- 
nimidyl)suberate and 10% DMSO 
for 15 min at room temperature. 
The cells were extracted in elec- 
trophoresis  sample  buffer, and  the  extracts  were  analyzed  on a 
5-15% gradient SDS polyacrylamide  gel, followed by autoradiog- 
raphy. 
highest natural producers of bFGF described (Moscatelli et 
al.,  1986a).  Cells of clones expressing these high levels of 
bFGF have a transformed phenotype (Quarto et al.,  1989). 
The number of receptors for bFGF on the transfected cells 
was compared to the  number of receptors on the  parental 
nontransfected  cells.  In  these  experiments,  cells  were  in- 
cubated with  10 ng/ml  z25I-bFGF, a concentration of bFGF 
sufficient to saturate bFGF receptors (data not shown).  ~25I- 
bFGF bound to matrix was removed with a wash with 2 M 
NaC1 at pH 7.4.  12~I-bFGF bound to receptors was then re- 
moved with a wash with 2 M NaC1 at pH 4.0 and quantitated 
in a  gamma scintillation counter. 
The cells of one transformed clone, B3, bound only 20 % 
as much t25I-bFGF to high-affinity receptors as control non- 
transfected cells (Fig.  1). Similar results were obtained with 
the  cells  from  another  independently  isolated  transfected 
clone (B1) that displayed a transformed phenotype (data not 
shown).  Cells from a clone transfected with the same plas- 
mid without the bFGF cDNA had the same number of recep- 
tors as nontransfected cells, demonstrating that transfection 
and the selection of the clones had no effect on receptor num- 
ber (Fig. 1). Cells from another clone (B14) transfected with 
the bFGF cDNA, which expressed 10-20%  of the amount 
of bFGF  in  clone B3  cells,  did  not  exhibit a  transformed 
phenotype.  These cells bound  as  much  z25I-bFGF to high 
affinity  receptors  as  the  nontransfected  cultures  (Fig.  1). 
Cells transfected with the hst/K-fgfoncogene also displayed 
a  lower number of receptors  than  nontransfected  cultures 
(Fig.  1).  In contrast,  there was no difference among these 
clones in the amount of t25I-bFGF bound to matrix (data not 
shown). 
Similar  results  were  obtained  when  the  receptors  were 
visualized  by  cross-linking  them to  radioactive  ~25I-bFGF 
(Fig. 2).  In these experiments, the cells were incubated for 
2  h  at 4°C  with  10  ng/ml  ~25I-bFGF, and  then the  cross- 
linking agent bis(sulfosuccinimidyl)suberate was added for 
15 min at room temperature. When extracts of the cells were 
analyzed  by  electrophoresis  followed  by  autoradiography, 
high molecular weight bands containing  radioactive bFGF 
could be detected in nontransfected NIH 3T3 cells.  These 
bFGF-receptor complexes had molecular weights of •165,000 
as described previously (Neufeld and Gospodarowicz, 1985; 
Olwin  and  Hauschka,  1986).  The  complexes detected  in 
cells  transfected  with  the  vector without  bFGF  cDNA or 
cells transfected with bFGF that have a nontransformed phe- 
notype were equal in intensity to the complexes detected in 
nontransfected cells. In cells transfected with bFGF that dis- 
play a transformed phenotype and cells transfected with the 
hst/K-fgf oncogene,  only  low  levels of ~25I-bFGF-receptor 
complex could be formed. 
The low level of bFGF receptors measured in clone B3 was 
not due to the occupancy of receptors by bFGF produced by 
the cells. To show this, clone B3 cells were washed with cold 
2 M NaC1 at pH 4.0, which has been shown to remove bFGF 
from receptors and from the matrix (Moscatelli,  1987), and 
then were used for binding studies.  The acid-washed clone 
B3  cells  bound  the  same  amount  of  ~2SI-bFGF as  PBS- 
washed cells (data not shown). The amount of bFGF bound 
by nontransfected NIH 3T3 ceils was not affected by the acid 
wash (data not shown), demonstrating that the wash proce- 
dure did not alter the receptor (Moscatelli, 1988). Similarly, 
the low number of receptors measured in the transfected cells 
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Figure 3. Effect of cell density 
on high-affinity bFGF recep- 
tors  of transfected and  non- 
transfected  NIH  31"3 cells. 
Nontransfected NIH 3T3 cells 
(o),  clone B3 cells (o),  and 
NIH 3T3 cells transfected with 
the  hst/K-fgf  oncogene  (zx) 
were plated at various concen- 
trations on 60-mm dishes in 
DME containing 10% calf se- 
rum. After 24 h at 37°C, the 
cells were washed twice with 
cold 2 M NaCI in 20 mM so- 
dium acetate, pH 4.0, and twice 
with PBS to remove  any bound 
bFGE  The  cells were incu- 
bated with 10 ng/ml t25I-bFGF 
for 2 h at 4°C, and the amount 
of mI-bFGF bound to high-affinity receptors was determined as 
described in the legend to Fig. 1. Parallel cultures were trypsinized 
and  the  number of cells  was  determined on a  particle counter 
(Coulter Electronics). 
was not due to the release of bFGF from the cells during the 
binding  assay,  which  then  competed  with  ~25I-bFGF for 
binding to its receptor. To demonstrate this,  clone B3 cells 
were washed with 2 M NaCl, pH 4.0, and incubated for 2 h 
at 4°C in binding buffer without ~2q-bFGE This buffer was 
collected,  nSI-bFGF was added to it,  and it was compared 
with fresh buffer in a binding assay on nontransfected NIH 
3T3 cells. A similar number of receptors was calculated for 
cells incubated in either buffer (data not shown). Thus, in- 
sufficient  amounts of bFGF are released by the transfected 
cells during the binding assay to compete with the ~25I-bFGE 
It has been reported that for some cell types bFGF recep- 
tors  appear  to  be  regulated  by cell  density  (Neufeld  and 
Gospodarowicz,  1985;  Rizzino et  al.,  1988).  Because  of 
differences in cell shape, cell-to-cell contact occurs at lower 
densities  for nontransformed NIH 3T3 cells than for trans- 
formed cells.  To determine whether the differences in recep- 
tor number between nontransformed and transformed cells 
was related to cell contact, we investigated whether receptor 
number was modulated by cell density.  There was virtually 
no change in receptor number in nontransfected NIH 3T3 
cells, clone B3 cells, or cells transfected with the hst/K-fgf 
oncogene over a  10-fold range of cell densities from sparse 
to highly confluent (Fig.  3). 
The normal number of receptors in clone BI4 was not due 
to an inability of these cells to downregulate their receptors. 
When 10 ng/ml of bFGF was added to these cultures and the 
cells were incubated at 37°C for 2 h, the number of receptors 
was decreased by 50%  (Fig. 4 A).  A  similar decrease was 
observed in nontransfected NIH 3T3 cells that had been in- 
cubated with  10 ng/ml bFGF at 370C for 2 h. When the 10 
ng/ml bFGF was added at 4°C  for  10 min,  there  was no 
change in receptor number, showing that this effect is not due 
merely to the addition of unlabeled bFGF (Fig.  4 A). Addi- 
tion of 10 ng/mi of exogenous bFGF for 2 h at 370C caused 
no further  decrease  in  the  number of bFGF receptors  in 
clone B3 cells or in cells transfected with the hst/K-fgf on- 
cogene (Fig. 4 B). Thus, the difference in receptor number 
between clones B3 and B14 is not related to their ability to 
Figure 4.  Downregulation of bFGF  receptors in tmnsfected and 
nontransfected NIH 3T3 cells. (A) Cultures containing ,~1.5 x  106 
cells/60-mm dish of nontransfected NIH 3I"3 cells (columns I-3) 
or clone BI4 cells (columns 4-6) were changed to fresh DME con- 
taining 10% calf serum and 10 ng/ml bFGF (columns 2 and 5) or 
no bFGF (columns 1, 3, 4, and 6) and incubated at 37°C for 2 h. 
Some of the cultures incubated without bFGF were then changed 
to cold DME containing 10% calf serum and 10 ng/ml bFGF and 
incubated at 4°C for 10 min (columns 3 and 6). All cultures were 
washed twice with cold 2 M NaCI in 20 mM sodium acetate, pH 
4.0, and twice with PBS to remove bound bFGE The cells were in- 
cubated with 10 ng/ml ~25I-bFGF for 2 h at 4°C, and the amount 
of J25I-bFGF bound to high-affinity receptors was determined as 
described in the legend to Fig. I. (B) Cultures containing ,,d.5  x 
l06 cells/60-mm dish of nontransfected NIH 3T3 cells (columns 1 
and 2), clone B3 cells (columns 3 and 4), or NIH 3T3 cells trans- 
fected with the hst/K-fgfoncogene (columns 5 and 6) were changed 
to fresh DME containing 10%  calf serum and  l0 ng/ml bFGF 
(columns 2, 4, and 6) or no bFGF (columns 1, 3, and 5) and in- 
cubated at 37°C for 2 h. Binding of t25I-bFGF to high-affinity re- 
ceptors was determined as described above. 
downmgulate receptors and  is  likely  to be a  result of the 
different levels  of bFGF expression in these cells. 
The amount of bFGF necessary to downregulate bFGF 
receptors on NIH 3'I"3 cells was investigated.  Subconfluent 
cultures of NIH 3T3 cells were incubated with various con- 
centrations of  bFGF for 5 h at 37°C. These cells were washed 
with 2 M NaCI at pH 4.0 to remove bound bFGF and were 
used for binding studies with '25I-bFGF at 4°C. Incubation 
with 0.5 ng/ml bFGF resulted in a half-maximal downregula- 
tion of bFGF receptors (Fig.  5). Maximal downregulation of 
bFGF receptors was obtained with 3 ng/nd bFGE In con- 
trast,  incubation of the cells  with bFGF had no effect  on 
'25I-bFGF  binding  to  the  matrix  (data  not  shown).  The 
transformed clone B3 cells have been demonstrated to re- 
lease  bFGF  into  their  medium  (Quarto  et  al.,  1989). 
Medium collected after a 24-h incubation on clone B3 cells 
and transferred to nontransformed NIH 31"3 cells for 5 h at 
37°C caused a downregulation ofbFGF receptors on the NIH 
3T3  cells to a  level  equivalent to that caused by 0.5 nghrd 
bFGF (Fig. 5, o), demonstrating that the bFGF released by 
these cells is capable of downregulating cellular receptors. 
Clone B1, B3, and B14 cells were transfected with bFGF 
cDNA that encodes four species of bFGF with molecular 
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Figure  5.  Dose-dependent 
downregulation of high-affin- 
ity  bFGF  receptors  in  NIH 
3"1"3 cells. Nontransfeeted  NIH 
3"13 cells (1.5 x  106/60 mm 
dish)  were changed  to fresh 
DME containing 10% calf se- 
rum and the indicated concen- 
trations of  bFGF and incubated 
at 37°C for 5 h. In addition, 
some cultures were incubated 
with  DME  containing  10% 
calf serum that had been con- 
ditioned by clone 133 cells for 
24 h  (o).  All cultures  were 
washed twice with cold 2 M NaCI in 20 mM sodium acetate, pH 
4.0, and twice with PBS to remove bound bFGE The cells were in- 
cubated with 10 ng/ml ~I-bFGF for 2 h at 4°C, and the amount 
of ~I-bFGF bound to high-affinity receptors was determined as 
described in the legend to Fig.  1. 
masses of 18, 22, 22.5, and 24 kD (Quarto et al., 1989; Flor- 
kiewicz and Sommer, 1989). These species arise from initia- 
tion of  translation at separate codons (Florkiewicz and Som- 
mer,  1989)  and  differ from each  other in  the  length  of 
NH2-terminal extensions (Florkiewiez and Sommer,  1989; 
Sommer et al., 1989). All four forms are present in extracts 
of these cells in approximately equal amounts (Quarto et al., 
1989). Western blot analysis of  medium conditioned for 24 h 
by clone B3 cells demonstrated that all four forms were also 
present  in  the  medium  (data  not  shown).  To  determine 
whether the downregulation of bFGF receptors could be at- 
tributed to expression of either 18-kD bFGF or the higher 
molecular weight bFGFs, receptor number on cells trans- 
fected with mutated bFGF cDNAs was  investigated. NIH 
3T3 cells transfected with bFGF cDNA in which the codon 
initiating  18-kD bFGF was mutated (365 bFGF cells) ex- 
press only 22-,  22.5- and 24-kD bFGFs (Quarto,  N.,  D. 
Talarico,  R.  Florkiewicz,  C.  Basilico,  and  D.  B.  Rifkin, 
manuscript in preparation). Clone 365 bFGF C7 cells, which 
express high levels of the higher molecular weight bFGFs 
and display a  transformed morphology, had low levels of 
bFGF receptor (Table I). Clone 365 bFGF C6 cells, which 
expressed lower levels of 22-, 22.5-, and 24-kD bFGFs, did 
not exhibit a transformed morphology and bound as much 
'25I-bFGF on high-affinity receptors as nontransfected cells 
(Table I). Thus, in cells that express only higher molecular 
weight bFGFs, transformation is also correlated with down- 
regulation of the bFGF receptor, suggesting that the higher 
molecular weight bFGFs are able to reach an extracytoplas- 
mic compartment and interact with the receptor. NIH 3T3 
cells transfected with a bFGF eDNA carrying a frame-shift 
insertion 5'to the initiation codon for 18-kD bFGF (43bFGF 
cells) synthesize only 18-kD bFGF (Quarto, N., D. Talarico, 
R.  Florkiewicz, C. Basilico, and D.  B.  Rifkin, manuscript 
in preparation). Clone 43 bFGF C31 cells that express high 
levels of 18-kD bFGF exhibit a transformed morphology and 
have down-regulated bFGF receptors (Table I).  Thus, the 
high level expression of either high molecular weight bFGFs 
or 18 kD bFGF results in transformation of cells and down- 
regulation of bFGF receptors. 
It appears that the decreased number of bFGF receptors 
Table I. Receptor Content of  NIH 3T3 Cells Transfected 
with Mutant bFGF cDNAs 
Cell line  12~I-bFGF bound 
fmol/lO 6 cells 
NIH 31"3  lmrental  49.8  -t- 0.5 
365 bFGF C'/  10.6  -t- 2.0 
365 bFGF  C6  46.6  +  3.0 
43 bFGF C31  3.4  5:0.8 
Cultures containing ",,1.5  x  106 cells/60-mm dish of nontransfected NIH 3T3 
cells or NIH 3T3 cells transfected with mutant bFGF cDNAs were washed 
twice with cold 2 M NaCI in 20 mM sodium acetate, pH 4.0, and twice with 
PETS. The cells were incubated with 10 ng/nd mI-bFGF for 2 h at 4"C, and 
the amount of t~I-bFGF bound to high-affinity receptors was determined as 
described in the legend to Fig.  1. 
in clone B3 cells is related to their high level expression of 
bFGF and is due to bFGF produced by the cells causing a 
downregulation of  bFGF receptors. We investigated whether 
receptor number in clone B3 cells could be restored to the 
level seen in non~ cells with suramin or protamine 
sulfate,  two  agents  that  block bFGF  interaction  with  its 
receptor (Coffey et al.,  1987; Neufeld and C~spodarowicz, 
1987).  Suramin,  which  also  prevents  the  interaction  of 
platelet-derived growth  factor  (PDGF)  with  its  receptor, 
reverses the morphological transformation of cells express- 
hag v-s/s (PDGF B chain) and decreases the rate of turnover 
of PDGF receptors in these cells (Garrett et al.  1984; Bet- 
sholtz et al.,  1986; Huang and Huang,  1988). 
Cell morphology and receptor number of clone B3 cells 
were not affected by protamine sulfate at concentrations up 
to 0.3 mg/ml (data not shown). However, when clone B3 cells 
were incubated with  1 mM suramin for 36 h,  their trans- 
formed morphology was lost (Fig. 6, Cand D). Suramin had 
a less dramatic effect on the morphology of NIH 3T3 cells 
transfected with the plasmid alone (Fig. 6, A and B), and had 
little effect on the morphology of NIH 3T3 cells transformed 
with the H-ras oncogene (Fig. 6, E and F). Suramin had no 
effect on the amount of bFGF produced by clone B3 cells. 
This was demonstrated by Western blot analysis of extracts 
of suramin-treated and untreated clone B3 cells (Fig. 7 A). 
Extracts of treated cells contained all four forms of bFGF in 
amounts equivalent to untreated cells. (In these gels, the 22- 
and 22.5-kD forms run together.) Dot blots of dilutions of 
the extracts confirmed that the total amount ofbFGF in sura- 
min-treated clone B3 cells was equal to the amount in non- 
treated cells (data not shown). However, suramin treatment 
resulted in an increase in the number of cell surface bFGF 
receptors, restoring them almost to control levels (Fig. 7 B). 
Suramin had little effect on receptor number in cells trans- 
fected with the plasmid alone or with the H-ras oncogene. 
A  similar reversal of the transformed morphology was ob- 
served when cells transfected with the hst/K-fgf oncogene 
were treated with suramin (data not shown). 
Discussion 
The decreased number of bFGF receptors in some clones of 
transfected NIH 3T3 cells can be correlated with their trans- 
formed  phenotype.  Clones  that  expressed  high  levels  of 
bFGF  exhibited  a  transformed  phenotype and  had  a  de- 
Moscatelli and Quarto Downregulation of FGF Receptors  2523 Figure 6.  Effect of suramin on the morphology of transfected NIH 3T3 cells. NIH 3T3 cells transfected with the Zip plasmid alone (A 
and B), clone B3 cells (C and D), and NIH 3T3 cells transfected with the H-ras oncogene (E and F) were incubated with DME containing 
10% calf serum and  1 mM suramin (B, D, and F) or no suramin (A, C, and E) as described in Materials and Methods. After a 36-h 
treatment at 37°C, the cells were photographed. Bar in F, 200 #m. 
creased number of bFGF receptors. Likewise, cells that ex- 
pressed the hst/K-fgfoncogene, a bFGF-like molecule that 
contains a signal sequence and is secreted, also exhibited a 
transformed phenotype and decreased bFGF receptors.  In 
contrast, clones that expressed lower levels  of bFGF were 
not transformed and had the same number of  bFGF receptors 
as nontransfected cells. Suramin, which has previously been 
shown to  block the  interaction  of bFGF  with  its  receptor 
(Huang et al., 1986; Coffey et al.,  1987),  restored the clones 
that expressed  high levels  of bFGF or the hst/K-fgf onco- 
gene to a  morphologically nontransformed phenotype and 
increased receptor number to control levels.  These results 
suggest that, in NIH 3T3 cells, bFGF transforms by interac- 
tion with its receptor. 
Expression of PDGF, transforming growth factor-a, granu- 
Iocyte-macrophage colony-stimulating factor, or colony-stim- 
ulating factor 1 in cells that have functional receptors for the 
appropriate growth factor also leads to transformation of the 
The Journal of Cell Biology, Volume  109, 1989  2524 Figure 7. Effect of suramin on bFGF expression and bFGF recep- 
tors in transfected NIH 3T3 cells. (A) Cultures of clone B3 cells in- 
cubated with no suramin (lane 1 ) or I mM suramin (lane 2) for 36 h 
were extracted, and the extracts were assayed for bFGF content by 
Western blot as described in Materials and Methods. (B) Parallel 
cultures of NIH 3T3 cells transfected with the Zip plasmid alone 
(columns 1 and 2), clone B3 cells (columns 3 and 4), and NIH 3T3 
cells transfected with the H-ras oncogene (columns 5 and 6) were 
incubated with DME containing 10% calf serum and 1 mM sura- 
min (columns 2, 4, and 6) or no suramin (columns 1, 3, and 5) as 
described  in Materials  and Methods.  After a  36-h treatment  at 
37°C, the cells were washed twice with cold 2 M NaC1 in 20 mM 
sodium acetate, pH 4.0, and twice with PBS. The cells were in- 
cubated with 10 ng/ml ~25I-bFGF for 2 h at 4°C, and the amount 
of t25I-bFGF bound to high-affinity receptors was determined as 
described in the legend to Fig.  1. 
cell (Betsholtz et al.,  1984; Garrett et al.,  1984; Huang et 
al.,  1984; Lang et al.,  1985; Rosenthal et al.,  1986; Retten- 
mier et al., 1987). These growth factors have signal sequences 
and the newly synthesized proteins are rapidly released into 
the endoplasmic reticulum. In the vesicular compartment of 
the cell, these growth factors may interact with newly synthe- 
sized receptors or are efficiently secreted and bind to cell- 
surface receptors. In contrast, bFGF lacks a classical signal 
sequence and appears to be primarily retained in an intracel- 
lular compartment. That bFGF interacts with its receptor in 
clone B3 cells indicates that despite the absence of a signal 
sequence some bFGF reaches an extracytoplasmic compart- 
ment where it can bind to its receptor. 
Because clone B3 cells synthesize four forms of bFGF, the 
form of bFGF that  stimulates  receptor downregulation in 
these cells is not certain. All four bFGFs were found in the 
conditioned medium, and therefore any of the forms may be 
responsible. In cells transfected with mutated bFGF cDNA 
that express only 18 kd bFGF, bFGF receptors were down- 
regulated, demonstrating that the information included in the 
NH2-terminal  extensions  of the  higher  molecular  weight 
bFGFs is not required for the release of bFGF and its modu- 
lation of its  receptor in  these cells.  Cells  transformed by 
transfection with bFGF cDNA mutated so that only the 22-, 
22.5-,  and  24-kD  bFGFs  are  expressed  also  had  down- 
regulated bFGF receptors, suggesting that the higher molec- 
ular weight bFGFs are also able to modulate receptor levels. 
However, the medium from these cultures contained, in ad- 
dition to 22-,  22.5-,  and 24-kD bFGFs,  small amounts of 
18-kD bFGF that most likely arose by proteolysis of the 
higher molecular weight forms (Quarto,  N.,  D.  Talarico, 
R. Florkiewicz, C. Basilico, and D.  B. Rifkin, manuscript 
in preparation). This raises the possibility that receptor down- 
regulation in these cells was also caused by 18-kD bFGE 
Nevertheless, other evidence suggests that each of the forms 
of bFGF is able to interact with the bFGF receptor. The 25- 
and 18-kD bFGFs isolated from guinea pig brain had equiva- 
lent  biological  activities  and  competed equally  with  m2sI- 
human bFGF for binding to the bFGF receptor (MoscateUi 
et al.,  1987).  In  addition,  high molecular weight human 
bFGFs were shown to possess  mitogenic activity for 3"1"3 
cells equivalent to that of 18-kD human bFGF, suggesting 
that all forms of human bFGF interact equally with the re- 
ceptor (Florkiewicz and Sommer, 1989). Finally, when 25- 
kD guinea pig bFGF was added to cultures of bovine capil- 
lary endothelial cells at 37°C,  it was internalized into the 
cells in an intact form (unpublished observations), suggest- 
ing that the 25-kD bFGF has an intrinsic ability to activate 
the receptor and does not need to be converted to the 18-kD 
form. Thus, the modulation of bFGF receptors on clone B3 
cells is most likely due to the combined action of all four 
forms of bFGE 
Although bFGF was found in the conditioned medium of 
clone B3 cells, it was present at <1% of the levels found in 
cell extracts (Quarto et al., 1989). The mechanism by which 
bFGF is released by these cells is unclear. A low-efficiency 
system for bFGF release may exist. In transfected NIH 3T3 
cells that express high levels of bFGF, enough bFGF may be 
released by this system to stimulate the cells.  This system 
may be more efficient in nontransfected cells that normally 
produce bFGF, allowing bFGF to be released in adequate 
amounts for autocrine activation even though these cells syn- 
thesize much lower levels of bFGF than clone B3 cells. Al- 
ternatively, bFGF may be released from clone B3 cells by 
cell lysis. Since it has been estimated that clone B3 cells con- 
tain 0.66 pg of bFGF per cell, the death of only 0.4% of the 
cells on a semiconfluent 60-mm dish would result in the re- 
lease of enough bFGF  to  give a  1  ng/ml  solution in  the 
medium. Addition of 1 ng/ml bFGF to nontransfected NIH 
3T3  cells  is  sufficient to  cause  downregulation  of bFGF 
receptors. However, in sparse cultures a greater proportion 
of the cells would have to lyse to release this concentration 
ofbFGE For clone B3 cells, the number of receptors per cell 
was not altered with changes in cell density over a  10-fold 
range, suggesting that cell lysis may not be a primary mecha- 
nism of release. 
The absence of any  alteration  in  the  number of bFGF 
receptors per cell with changes in cell density for NIH 3T3 
cells is in contrast to what has been reported for bFGF recep- 
tors in baby hamster kidney, normal rat kidney, and 3T3 cells 
(Neufeld and Gospodarowicz, 1985; Rizzino et al.,  1988). 
This difference may be explained by the fact that the earlier 
investigators did not separate  receptor-bound bFGF  from 
matrix-bound bFGF in their studies.  When matrix-bound 
bFGF is eliminated, no difference  in the number of receptors 
per cell can be observed over a range of cell densities in NIH 
3T3 cells (Fig. 3) or BHK cells (unpublished observations). 
Moscatelli and Quarto Downregulation of FGF Receptors  2525 That transfection of NIH 3T3 cells with the hst/K-fgfon- 
cogene also results in the downregulafion of bFGF receptors 
suggests that these homologous molecules may  share  the 
same receptors.  This possibility is supported by the finding 
that crude preparations  of the hst/K-fgf oncogene product 
compete with ~eSI-bFGF for binding to its receptor (unpub- 
lished observations). In this respect,  the hst/K-fgfoncogene 
product is similar  to aFGF, which has also been shown to 
share receptors with bFGF. Thus, specific receptors for each 
member of the FGF family  may  not exist,  and  the FGF 
receptors may have overlapping affinities for different FGF- 
like  molecules. 
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